SEC Form 4 · accession 0001493152-17-004209
OncBioMune Pharmaceuticals, Inc · OBMP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Albert Kucharchuk
Officer — Chief Financial Officer
Period of report
Mar 10, 2017
Accepted (ET)
Apr 20, 2017 · 8:45 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001362703
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emplyee Stock Option (right to buy)F1 | $0.25 | Mar 10, 2017 | A | 2,000,000 | A | — | Mar 10, 2027 | Common Stock | 2,000,000 | 2,000,000 | D |
Explanation of responses
- F1One-third of the Stock Options vest on March 10, 2018, March 10, 2019 and March 10, 2020.